Esketamine combined with sertraline for brain altered regional homogeneity in patients with major depressive disorder: A preliminary study.
Brain research bulletin November 13, 2025 Xiang Liu, Ziyi Hua, Yongqiang Shu et al. 1 citation
In patients with major depressive disorder, a two-week course of intravenous esketamine combined with sertraline led to improvements in anxiety, depression, suicidal ideation, and cognitive scores. Brain imaging revealed that before treatment, patients had abnormal spontaneous brain activity compared to healthy individuals, with increased regional homogeneity in several brain regions and decreased homogeneity in others. After treatment, the local consistency of the left middle temporal gyrus reversed toward normal levels. Changes in this region correlated with anxiety scale scores, suggesting it may be a key hub linked to depression severity and recovery.